Radioablation for Ventricular Tachycardia: Current Evidence and Future Perspectives

Area of Science:

• Cardiology
• Radiation Oncology
• Medical Physics

Background:

• Ventricular tachycardia (VT) is a life-threatening arrhythmia.
• Conventional treatments like medication and ablation are often ineffective for refractory VT.
• Stereotactic arrhythmia radioablation (STAR) is a novel noninvasive approach.

Purpose of the Study:

• To review the current evidence on STAR for refractory VT.
• To summarize mechanisms of action, patient selection, and treatment planning.
• To assess the clinical outcomes and safety of STAR.

Main Methods:

• Review of preclinical and early clinical studies on STAR.
• Analysis of data from clinical trials and prospective registries.
• Examination of the role of the European STOPSTORM consortium.

Main Results:

• STAR delivers precise, high-dose radiation to arrhythmogenic tissue, minimizing collateral damage.
• Early studies indicate rapid antiarrhythmic effects via modulation of cardiac conduction.
• Clinical data show significant reductions in VT burden with acceptable short-term safety.

Conclusions:

• STAR is a promising noninvasive alternative for refractory VT when other therapies fail.
• Further research is needed to evaluate long-term efficacy and potential late toxicities.
• Multidisciplinary collaboration is crucial for standardizing STAR protocols and ensuring patient safety.